Page 266 - Read Online

Page 20 of 23 Parsons et al. J Cancer Metastasis Treat 2018;4:19 I http://dx.doi.org/10.20517/2394-4722.2018.11

121. Collette J, Le Bourhis X, Adriaenssens E. Regulation of human breast cancer by the long non-coding RNA H19. Int J Mol Sci
2017;18:E2319.
122. Pachnis V, Brannan CI, Tilghman SM. The structure and expression of a novel gene activated in early mouse embryogenesis. EMBO J
1988;7:673-81.
123. Poirier F, Chan CT, Timmons PM, Robertson EJ, Evans MJ, Rigby PW. The murine H19 gene is activated during embryonic stem cell
differentiation in vitro and at the time of implantation in the developing embryo. Development 1991;113:1105-14.
124. Rachmilewitz J, Goshen R, Ariel I, Schneider T, de Groot N, Hochberg A. Parental imprinting of the human H19 gene. FEBS Lett
1992;309:25-8.
125. Bartolomei MS, Webber AL, Brunkow ME, Tilghman SM. Epigenetic mechanisms underlying the imprinting of the mouse H19 gene.
Genes Dev 1993;7:1663-73.
126. Sparago A, Cerrato F, Vernucci M, Ferrero GB, Silengo MC, Riccio A. Microdeletions in the human H19 DMR result in loss of IGF2
imprinting and Beckwith-Wiedemann syndrome. Nat Genet 2004;36:958-60.
127. DeBaun MR, Tucker MA. Risk of cancer during the first four years of life in children from The Beckwith-Wiedemann Syndrome
Registry. J Pediatr 1998;132:398-400.
128. Brunkow ME, Tilghman SM. Ectopic expression of the H19 gene in mice causes prenatal lethality. Genes Dev 1991;5:1092-101.
129. Heery R, Finn S, Cuffe S, Gray SG. Long non-coding RNAs: key regulators of epithelial-mesenchymal transition, tumour drug
resistance and cancer stem cells. Cancers (Basel) 2017;9:E38.
130. Riaz M, Berns EMJJ, Sieuwerts AM, Ruigrok-Ritstier K, de Weerd V, Groenewoud A, Uitterlinden AG, Look MP, Klijn JG, Sleijfer
S, Foekens JA, Martens JW. Correlation of breast cancer susceptibility loci with patient characteristics, metastasis-free survival, and
mRNA expression of the nearest genes. Breast Cancer Res Treat 2012;133:843-51.
131. Luo M, Li Z, Wang W, Zeng Y, Liu Z, Qiu J. Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2
and inhibiting E-cadherin expression. Cancer Lett 2013;333:213-21.
132. Berx G, Van Roy F. The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant
progression. Breast Cancer Res 2001;3:289-93.
133. Ishikawa A, Kitajima S, Takahashi Y, Kokubo H, Kanno J, Inoue T, Saga Y. Mouse Nkd1, a Wnt antagonist, exhibits oscillatory gene
expression in the PSM under the control of Notch signaling. Mech Dev 2004;121:1443-53.
134. Katoh M, Katoh M. WNT signaling pathway and stem cell signaling network. Clin Cancer Res 2007;13:4042-5.
135. Smaldone MC, Davies BJ. BC-819, a plasmid comprising the H19 gene regulatory sequences and diphtheria toxin A, for the potential
targeted therapy of cancers. Curr Opin Mol Ther 2010;12:607-16.
136. Scaiewicz V, Sorin V, Fellig Y, Birman T, Mizrahi A, Galula J, Abu-Lail R, Shneider T, Ohana P, Buscail L, Hochberg A, Czerniak A.
Use of H19 gene regulatory sequences in DNA-based therapy for pancreatic cancer. J Oncol 2010;2010:178174.
137. Amit D, Hochberg A. Development of targeted therapy for a broad spectrum of cancers (pancreatic cancer, ovarian cancer, glioblastoma
and HCC) mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory
sequences. Int J Clin Exp Med 2012;5:296-305.
138. Li J, Chen Y, Chen Z, He A, Xie H, Zhang Q, Cai Z, Liu Y, Huang W. SPRY4-IT1: a novel oncogenic long non-coding RNA in human
cancers. Tumor Biol 2017;39:1010428317711406.
139. Khaitan D, Dinger ME, Mazar J, Crawford J, Smith MA, Mattick JS, Perera RJ. The melanoma-upregulated long noncoding RNA
SPRY4-IT1 modulates apoptosis and invasion. Cancer Res 2011;71:3852-62.
140. Xie M, Nie FQ, Sun M, Xia R, Liu YW, Zhou P, De W, Liu XH. Decreased long noncoding RNA SPRY4-IT1 contributing to gastric
cancer cell metastasis partly via affecting epithelial-mesenchymal transition. J Transl Med 2015;13:250.
141. Cui F, Wu D, He X, Wang W, Xi J, Wang M. Long noncoding RNA SPRY4-IT1 promotes esophageal squamous cell carcinoma cell
proliferation, invasion, and epithelial-mesenchymal transition. Tumour Biol 2016;37:10871-6.
142. Zhang CY, Li RK, Qi Y, Li XN, Yang Y, Liu DL, Zhao J, Zhu DY, Wu K, Zhou XD, Zhao S. Upregulation of long noncoding RNA
SPRY4-IT1 promotes metastasis of esophageal squamous cell carcinoma via induction of epithelial-mesenchymal transition. Cell Biol
Toxicol 2016;32:391-401.
143. Zhou M, Zhang XY, Yu X. Overexpression of the long non-coding RNA SPRY4-IT1 promotes tumor cell proliferation and invasion by
activating EZH2 in hepatocellular carcinoma. Biomed Pharmacother 2017;85:348-54.
144. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, Richardson JA, Bassel-Duby R, Olson EN. The endothelial-specific
microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008;15:261-71.
145. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, Ivey KN, Bruneau BG, Stainier DY, Srivastava D. miR-126 regulates
angiogenic signaling and vascular integrity. Dev Cell 2008;15:272-84.
146. Yu X, Zheng H, Chan MT V, Wu WK. HULC: an oncogenic long non-coding RNA in human cancer. J Cell Mol Med 2017;21:410-7.
147. Panzitt K, Tschernatsch MMO, Guelly C, Moustafa T, Stradner M, Strohmaier HM, Buck CR, Denk H, Schroeder R, Trauner M,
Zatloukal K. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA.
Gastroenterology 2007;132:330-42.
148. Zhao Y, Guo Q, Chen J, Hu J, Wang S, Sun Y. Role of long non-coding RNA HULC in cell proliferation, apoptosis and tumor metastasis
of gastric cancer: a clinical and in vitro investigation. Oncol Rep 2014;31:358-64.
149. Hämmerle M, Gutschner T, Uckelmann H, Ozgur S, Fiskin E, Gross M, Skawran B, Geffers R, Longerich T, Breuhahn K, Schirmacher
P, Stoecklin G, Diederichs S. Posttranscriptional destabilization of the liver-specific long noncoding RNA HULC by the IGF2 mRNA-
binding protein 1 (IGF2BP1). Hepatology 2013;58:1703-12.